Ruchit Sood1,2, Michael Camilleri3, David J Gracie1,2, Matthew J Gold4, Natalie To1,2, Graham R Law5, Alexander C Ford1,2. 1. Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK. 2. Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK. 3. Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic, Rochester, Minnesota, USA. 4. School of Medicine, University of Leeds, Leeds, UK. 5. Division of Epidemiology and Biostatistics, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Abstract
OBJECTIVES: Symptom-based criteria to diagnose irritable bowel syndrome (IBS) positively perform only modestly. Our aim was to assess whether including other items from the clinical history and limited diagnostic evaluation improves their performance. METHODS: We collected complete symptom, colonoscopy, and histology data from 318 consecutive, unselected adult patients with lower gastrointestinal (GI) symptoms in secondary care. All participants underwent colonoscopy, with relevant organic findings recorded. The reference standard used to define the presence of true IBS was patient-reported lower abdominal pain or discomfort associated with a change in bowel habit, in the absence of organic GI disease. Sensitivity, specificity, and positive and negative likelihood ratios (LRs), with 95% confidence intervals, were calculated for Rome III criteria, as well as for modifications, incorporating nocturnal stools, results of simple blood tests (hemoglobin and C-reactive protein (CRP)), measures of somatization, and/or affective disorders (hospital anxiety or depression scale (HADS) score). RESULTS: The sensitivity and specificity of the Rome III criteria for identifying IBS was 69.6%, and 82.0%, respectively, with positive and negative LRs of 3.87 and 0.37, respectively. Clinically useful enhancements in positive LRs were provided by combining Rome III criteria with: (a) high level of somatization (7.27); (b) normal hemoglobin and CRP with HADS score of ≥8 (5.04); (c) normal hemoglobin and CRP with a high level of somatization (7.56); or (d) no nocturnal passage of stool with a high level of somatization (17.3). Specificity was ≥95% with each of these modifications. CONCLUSIONS: Incorporating nocturnal stools, somatization, and affective disorders from the clinical history, and hemoglobin and CRP measurements, enhances the positive LR and specificity of symptom-based Rome III criteria for IBS.
OBJECTIVES: Symptom-based criteria to diagnose irritable bowel syndrome (IBS) positively perform only modestly. Our aim was to assess whether including other items from the clinical history and limited diagnostic evaluation improves their performance. METHODS: We collected complete symptom, colonoscopy, and histology data from 318 consecutive, unselected adult patients with lower gastrointestinal (GI) symptoms in secondary care. All participants underwent colonoscopy, with relevant organic findings recorded. The reference standard used to define the presence of true IBS was patient-reported lower abdominal pain or discomfort associated with a change in bowel habit, in the absence of organic GI disease. Sensitivity, specificity, and positive and negative likelihood ratios (LRs), with 95% confidence intervals, were calculated for Rome III criteria, as well as for modifications, incorporating nocturnal stools, results of simple blood tests (hemoglobin and C-reactive protein (CRP)), measures of somatization, and/or affective disorders (hospital anxiety or depression scale (HADS) score). RESULTS: The sensitivity and specificity of the Rome III criteria for identifying IBS was 69.6%, and 82.0%, respectively, with positive and negative LRs of 3.87 and 0.37, respectively. Clinically useful enhancements in positive LRs were provided by combining Rome III criteria with: (a) high level of somatization (7.27); (b) normal hemoglobin and CRP with HADS score of ≥8 (5.04); (c) normal hemoglobin and CRP with a high level of somatization (7.56); or (d) no nocturnal passage of stool with a high level of somatization (17.3). Specificity was ≥95% with each of these modifications. CONCLUSIONS: Incorporating nocturnal stools, somatization, and affective disorders from the clinical history, and hemoglobin and CRP measurements, enhances the positive LR and specificity of symptom-based Rome III criteria for IBS.
Authors: M P Jones; W D Chey; S Singh; H Gong; R Shringarpure; N Hoe; E Chuang; N J Talley Journal: Aliment Pharmacol Ther Date: 2014-01-06 Impact factor: 8.171
Authors: R C Spiller; D J Humes; E Campbell; M Hastings; K R Neal; G E Dukes; P J Whorwell Journal: Aliment Pharmacol Ther Date: 2010-09 Impact factor: 8.171
Authors: Brennan M R Spiegel; Mary Farid; Eric Esrailian; Jennifer Talley; Lin Chang Journal: Am J Gastroenterol Date: 2010-03-02 Impact factor: 10.864
Authors: Michael Camilleri; Sanna McKinzie; Irene Busciglio; Phillip A Low; Seth Sweetser; Duane Burton; Kari Baxter; Michael Ryks; Alan R Zinsmeister Journal: Clin Gastroenterol Hepatol Date: 2008-05-05 Impact factor: 11.382
Authors: Alexander C Ford; Brennan M R Spiegel; Nicholas J Talley; Paul Moayyedi Journal: Clin Gastroenterol Hepatol Date: 2009-08-12 Impact factor: 11.382
Authors: Gilles Macaigne; Pierre Lahmek; Christophe Locher; Bruno Lesgourgues; Laurent Costes; Max Pierre Nicolas; Anne Courillon-Mallet; Jean-Michel Ghilain; Guy Bellaïche; Stéphanie de Montigny-Lehnardt; Georges Barjonet; René-Louis Vitte; Roger Faroux; Benedicte Lambare; Antoine Fleury; Alexandre Pariente; Stéphane Nahon Journal: Am J Gastroenterol Date: 2014-07-08 Impact factor: 10.864
Authors: M Camilleri; A Shin; I Busciglio; P Carlson; A Acosta; A E Bharucha; D Burton; J Lamsam; A Lueke; L J Donato; A R Zinsmeister Journal: Neurogastroenterol Motil Date: 2014-09-22 Impact factor: 3.598
Authors: Paul Moayyedi; Fermín Mearin; Fernando Azpiroz; Viola Andresen; Giovanni Barbara; Maura Corsetti; Anton Emmanuel; A Pali S Hungin; Peter Layer; Vincenzo Stanghellini; Peter Whorwell; Frank Zerbib; Jan Tack Journal: United European Gastroenterol J Date: 2017-09-28 Impact factor: 4.623
Authors: Ramesh P Arasaradnam; Steven Brown; Alastair Forbes; Mark R Fox; Pali Hungin; Lawrence Kelman; Giles Major; Michelle O'Connor; Dave S Sanders; Rakesh Sinha; Stephen Charles Smith; Paul Thomas; Julian R F Walters Journal: Gut Date: 2018-04-13 Impact factor: 23.059
Authors: Paul Moayyedi; Christopher N Andrews; Glenda MacQueen; Christina Korownyk; Megan Marsiglio; Lesley Graff; Brent Kvern; Adriana Lazarescu; Louis Liu; William G Paterson; Sacha Sidani; Stephen Vanner Journal: J Can Assoc Gastroenterol Date: 2019-01-17